Trial Profile
A study assessing the potential effects of food intake on pharmacokinetics of AZP2006 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2019
Price :
$35
*
At a glance
- Drugs Ezeprogind (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors AlzProtect
- 20 Feb 2019 Status changed from recruiting to completed, according to an AlzProtect media release.
- 25 Sep 2018 New trial record